Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-816-6640
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.66 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions
What is Nabriva Therapeutics' stock symbol?
Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."
How were Nabriva Therapeutics' earnings last quarter?
Nabriva Therapeutics PLC - (NASDAQ:NBRV) posted its earnings results on Friday, May, 10th. The biotechnology company reported ($0.29) EPS for the quarter, beating the Zacks' consensus estimate of ($0.32) by $0.03. The biotechnology company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $0.56 million. Nabriva Therapeutics had a negative net margin of 3,194.72% and a negative return on equity of 119.75%. View Nabriva Therapeutics' Earnings History.
When is Nabriva Therapeutics' next earnings date?
What price target have analysts set for NBRV?
7 brokers have issued 12 month price objectives for Nabriva Therapeutics' stock. Their forecasts range from $2.00 to $13.00. On average, they expect Nabriva Therapeutics' stock price to reach $8.00 in the next year. This suggests a possible upside of 281.0% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics.
What is the consensus analysts' recommendation for Nabriva Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics.
What are Wall Street analysts saying about Nabriva Therapeutics stock?
Here are some recent quotes from research analysts about Nabriva Therapeutics stock:
- 1. HC Wainwright analysts commented, "We await details on the structure of a potential EU partnership to add the EU to our model. As such, any future revenues from the EU represent upside to our current estimates. Expecting lefamulin’s U.S. approval on August 19, 2019 PDUFA date. As a reminder, Nabriva reported on February 18 that the FDA has accepted the NDAs for lefamulin in both IV and oral formulations for the treatment of CABP based on a 6-month Priority Review target, with an August 19, 2019 PDUFA date. Since there are no current plans for an AdCom meeting for lefamulin’s NDAs as indicated in the FDA’s acceptance letter, we anticipate its approval for the U.S. market around its assigned PDUFA date. Furthermore, lefamulin is eligible for an additional five years of regulatory exclusivity as a Product (QIDP) product if it is approved." (5/9/2019)
- 2. Northland Securities analysts commented, "We are reiterating our OP rating. We see a clear path to approval for CONTEPO for the treatment of cUTIs w/ a PDUFA action date of April 30th. Similarly, we see a clear path to approval for both oral and IV formulations of Lefamulin for the treatment of 19th PDUFA action date. These events should serve as major near-term catalysts to its shares. We anticipate commercialization of both products in 2H19. Pre-open, Nabriva reported fiscal 2018 year results, with the 4Q EPS loss of ($0.38), comparing to our estimate of ($0.35). The differential reflected higher RD expense which likely included non-cash items. The Company ended the December 31st period with cash and equivalents of $102.2MM, which should prove sufficient to fund operations into 2Q2020." (3/12/2019)
- 3. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (2/6/2019)
Has Nabriva Therapeutics been receiving favorable news coverage?
Headlines about NBRV stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nabriva Therapeutics earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Nabriva Therapeutics.
Are investors shorting Nabriva Therapeutics?
Nabriva Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 1,652,574 shares, an increase of 142.3% from the April 15th total of 682,064 shares. Based on an average daily volume of 1,685,500 shares, the days-to-cover ratio is currently 1.0 days. Currently, 3.4% of the company's stock are short sold. View Nabriva Therapeutics' Current Options Chain.
Who are some of Nabriva Therapeutics' key competitors?
Some companies that are related to Nabriva Therapeutics include Ascendis Pharma A/S (ASND), Beigene (BGNE), Marina Biotech (MRNA), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), FibroGen (FGEN), ACADIA Pharmaceuticals (ACAD), Mirati Therapeutics (MRTX), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), United Therapeutics (UTHR), Uniqure (QURE) and Global Blood Therapeutics (GBT).
What other stocks do shareholders of Nabriva Therapeutics own?
Who are Nabriva Therapeutics' key executives?
Nabriva Therapeutics' management team includes the folowing people:
- Mr. Steven P. Gelone, Pres & COO (Age 51)
- Dr. Colin Broom, Consultant & Director (Age 63)
- Mr. Gary L. Sender, Chief Financial Officer (Age 57)
- Mr. Theodore R. Schroeder, CEO & Director (Age 64)
- Mr. Thomas Lembck, Chief Information Officer
Who are Nabriva Therapeutics' major shareholders?
Nabriva Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (0.63%), FMR LLC (0.47%), Fosun International Ltd (0.10%), Wedbush Securities Inc. (0.01%) and Clear Harbor Asset Management LLC (0.01%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, George Harrison Talbot, Hbm Healthcare Investments (Ca, Jennifer Schranz, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Nabriva Therapeutics.
Which major investors are selling Nabriva Therapeutics stock?
Which major investors are buying Nabriva Therapeutics stock?
NBRV stock was bought by a variety of institutional investors in the last quarter, including FMR LLC and Fosun International Ltd. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Insider Buying and Selling for Nabriva Therapeutics.
How do I buy shares of Nabriva Therapeutics?
Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nabriva Therapeutics' stock price today?
One share of NBRV stock can currently be purchased for approximately $2.10.
How big of a company is Nabriva Therapeutics?
Nabriva Therapeutics has a market capitalization of $1.46 billion and generates $9.66 million in revenue each year. The biotechnology company earns $-114,780,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. View Additional Information About Nabriva Therapeutics.
What is Nabriva Therapeutics' official website?
How can I contact Nabriva Therapeutics?
Nabriva Therapeutics' mailing address is 56 FITZWILLIAM SQUARE, DUBLIN L2, 19406. The biotechnology company can be reached via phone at 610-816-6640 or via email at [email protected]
MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
